HRSA Tells Drugmakers To Repay Hospitals for 340B Orphan Drug Overcharges

by Admin | October 16, 2014 12:40 pm

October 16, 2014—The Health Resources and Services Administration has told an undetermined number of orphan drug manufacturers that they are out of compliance with 340B statutory requirements and their pricing agreements with the government and must notify it of their plans to repay affected rural and freestanding cancer hospitals for overcharges. It is HRSA’s most significant enforcement action affecting drug manufacturers in the 340B program’s 22-year history. 

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[1].    Already registered? Click here to login[2]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

  1. Click here to register:
  2. Click here to login:

Source URL: